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Individualized IMRT treatment 
approach for cervical lymph node 
metastases of unknown primary
In approximately 3–5% of patients pre-
senting with squamous cell cancer (SCC) 
metastases in cervical lymph nodes, the 
primary is not found despite extensive 
clinical evaluation [1, 2]. Treatment of 
those patients remains controversial lack-
ing evidence from prospective random-
ized trials. Recommendations include 
neck dissection and/or radio(chemo)ther-
apy. For more advanced stages, multimod-
al treatment is recommended. Induction 
chemotherapy before radio(chemo)ther-
apy followed by surgery depending on re-
sponse may be an additional option [2, 3, 
4]; however, its value is not proven. The 
main controversial aspect is the radio-
therapy (RT) treatment volume. Planning 
treatment volumes (PTVs) often include 
the affected lymph node region as well as 
contralateral cervical lymph nodes and 
the mucosal sites of the pharynx in order 
to cover a putative primary (comprehen-
sive RT) [5].
Several retrospective single institution 
studies compared comprehensive con-
ventional radiation to involved field radi-
ation. While some groups demonstrated 
better local outcome using extended fields 
[5, 6, 7], others did not show an advantage 
for more extensive RT [4, 8, 9, 10]. Fur-
thermore, omitting hypopharyngeal and 
laryngeal mucosa seems to be feasible as 
well [1, 11].
Introduction of intensity-modulat-
ed radiotherapy (IMRT) in patients with 
head and neck cancer showed an im-
proved therapeutic ratio compared to 
historic conventional three-dimension-
al techniques [12]. Recently, in the era of 
IMRT, several study groups used IMRT in 
patients with cervical lymph node metas-
tases of unknown primary cancer (UPC) 
and confirmed those good results [13, 14, 
15, 16, 17, 18, 19].
The purpose of this article is to evalu-
ate the outcome of risk-adapted PTVs in 
patients with cervical lymph node metas-
tases of UPC treated with IMRT.
Material and methods
Patients
From January 2006 to November 2012, 28 
consecutive patients presenting with cer-
vical lymph node metastases of UPC were 
treated in our department with IMRT ei-
ther postoperatively (n=20) or as defini-
tive treatment (n=8). Diagnosis was prov-
en histologically in all patients show-
ing metastases of SCC. PET-CT was per-
formed routinely before treatment start 
and was considered for delineation. Pa-
tient- and treatment-related parameters 
are summarized in . Tab. 1. Mean/me-
dian follow-up time was 31.6/30.5 months 
(range 3–78 months). Details regarding 
surgical neck dissection prior to radiation 
(n=20) or as postradiation elective neck 
dissection (END) are listed in . Tab. 2.
Regular follow-up visits were carried 
out in our joint clinic at the Department 
of Otorhinolaryngology, Head and Neck 
Surgery. Institutional standards for patient 
assessment included physical examination 
and flexible fiber optic endoscopy approx-
imately every 2 months in the first year of 
follow-up, every 3 months in the second 
to third year and every 6 months in the 
fourth to fifth years.
Treatment
IMRT
Unilateral irradiation was preferred. 
Based on individual risk factors includ-
ing clinical, surgical, histopathological, 
and imaging information, we enlarged 
treatment fields to the putative mucosal 
site or the contralateral neck. One crucial 
risk factor was suspicious enhancement of 
contralateral lymph nodes or oropharyn-
geal structures in PET-CT (n=4). In those 
cases, a biopsy of the questionable region 
was carried out revealing no malignancy. 
Nevertheless a certain risk of involvement 
was supposed in that case—which was the 
reason to extend PTVs. Other risk factors 
suggestive for bilateral nodal irradiation 
were status after pT1 floor of the mouth 
carcinoma in the past (n=1), recurrent 
lymph node metastases (n=1), and level I 
involvement (n=2). “Classical” extensive 
bilateral treatment was reserved for N2c 
and bilateral N3 patients (n=5; postoper-
ative: n=1; definitive: n=4). One patient 
with extensive N3 disease (116 ccm) was 
only treated unilaterally due to advanced 
age and poor general condition. Doses 
and PTVs based on the affected cervical 
node levels are shown in . Tab. 3.
. Fig. 1, 2, and . Fig. 3 demonstrate 
uni- and bilateral RT volumes. We used si-
multaneously integrated boost (SIB) tech-
nique in all patients [20, 21]. SIB-IMRT 
was performed using the schedules below.
In definitive IMRT patients (n=8):
F  SIB2.00: 35 fractions with daily SIB 
doses of 2.00 Gy (PTV1)/1.70 Gy 
(PTV2) and 1.54 Gy (PTV3) to a total 
boost dose of 70.00 Gy (five fractions 
a week).
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F  SIB2.11: 33 fractions with daily SIB 
doses of 2.11 (PTV1)/1.80 Gy (PTV 
2) and 1.64 Gy (PTV3) to a total 
boost dose of 69.60 Gy (five fractions 
a week).
In postoperative patients (n=20):
F  SIB2.00: 32–33 fractions with daily 
SIB doses of 2.00 Gy (PTV 1)/1.80 Gy 
(PTV2)/1.64 Gy (PTV3) to a total 
boost dose of 64–66.00 Gy (five frac-
tions a week).
F  SIB2.11: 33 fractions of daily SIB dos-
es of 2.11 (PTV1)/1.80 Gy (PTV 2) 
and 1.64 Gy (PTV3) to a total boost 
dose of 69.60 Gy (five fractions a 
week).
F  SIB2.2: 30 fractions with daily SIB 
doses of 2.2 Gy (PTV1)/2.0 Gy 
(PTV2) and 1.64 Gy (PTV3) to a to-
tal dose of 66.00 Gy (five fractions a 
week) (carried out in 1 patient)
In 1 patient two IMRT series were carried 
out instead of SIB (50 Gy, 16 Gy boost, sin-
gle dose: 2.0 Gy, 6 fractions/week).
The dose was normalized to the mean 
dose in PTV1. For intensity optimization, 
the prescribed dose encompassed at least 
95% of the PTV. Additionally, no more 
than 2% of any PTV received >110% of its 
prescribed dose, whereas no more than 
1% of any PTV received <93% of the pre-
scribed dose.
Target volumes were delineated as fol-
lows: the involved lymph nodes included 
the gross extent of primary disease, tak-
ing clinical and radiological findings in-
to account; clinical target volume (CTV) 
was defined by adding 10–15 mm margin 
to the gross tumor volume (GTV), anoth-
er 2–3 mm margin was added from CTV 
to PTV 1 dependent on proximity to crit-
ical structures (e.g., spinal cord or brachi-
al plexus); PTV2 covered areas consid-
ered at high risk for potential microscop-
ic disease; and PTV3 included the clinical-
ly negative mucosa or lymphatic pathways 
(elective PTV coverage).
In patients with substantial parts of 
the pharynx and/or larynx involved in 
the PTV, 2.0 Gy per session was given. To 
ensure sufficient dose delivery to the skin 
close to GTVs, bolus material (0.5–1 cm 
thickness) was used in patients with skin 
involvement and/or <5 mm between GTV 
and the overlying skin.
Irradiation was delivered with five or 
seven coplanar beam angles by a 6-MV 
dynamic MLC system (Varian Medical 
Systems, Palo Alto, CA, USA) using the 
sliding window technique, or using the 
volumetric modulated rapid arc technique 
(VMAT, since April 2010). Patients were 
immobilized from head to shoulders us-
ing a commercially available thermoplas-
tic mask in supine position.
Systemic therapy
Systemic therapy preferably consisted 
of cisplatin (40 mg/m2 weekly) and was 
switched to cetuximab in case of cisplatin-
related adverse effects (cetuximab load-
ing dose: 400 mg/m2 followed by weekly 
applications of 250 mg/m2 [22]). For pa-
tients with contraindications against cis-
platin, cetuximab was favored primarily. 
The indication for systemic therapy was 
made based on extent of nodal involve-
ment, resection status, extra-nodal ex-
tension, age, and Karnofsky performance 
score. In 2 patients with extended disease 
(cN3 and cN2c), three cycles of neoadju-
vant chemotherapy with TPF (docetaxel 
Tab. 1 Patient- and treatment-related 
parameters
Mean age (years) 66 (range 45–86)
Gender
– Male 22 (79%)
– Female 6 (21%)
RT sequence
– Postoperative IMRT 20 (71%)
– Definitive IMRT 8 (29%)
RT volume
– Bilateral IMRT 13 (46%)
– Unilateral IMRT 15 (54%)
RT doses
– 33×2=66 Gy 16 (57%)
– 32×2=64 Gy 1 (4%)
– 35×2=70 Gy 2 (7%)
– 30×2.2=66 Gy 1 (4%)
– 33×2.11=69.63 Gy 7 (24%)
– 32×2.11=67.52 Gy 1 (4%)
N status
– N1 2 (7%)
– N2a 8 (28%)
– N2b 12 (43%)
– N2c 3 (11%)
– N3 3 (11%)
Lymph node involvement
– Level I 2
– Level lI 18
– Level III 9
– Level IV 5
– Level V 1
– Bilateral 4
ECE 11 (39%)
R1/2 6/20 (21%)
Cisplatin or cetuximab 
concomitant
20 (71%)
Preoperative chemo-
therapy
2 (7%)
ECE extra capsular extension, RT radiotherapy, 
IMRT intensity-modulated radiotherapy.
Tab. 2 Extent of neck dissection and 
number of positive lymph nodes for all 
20 patient receiving surgery prior to radia-
tion. In 4 of 8 patients with definitive ir-
radiation, an elective neck dissection (END) 
was performed
  Extent of neck 
dissection (level)
Positive lymph 
nodes
1 II–IV left 4/31
2 II–IV left 1/12
3 II–IV left 9/24
4 I–IV right 2/6
5 II–III left 2/18
6 I–V right 18/30
7 I–IV right 3/14
8 II–IV right 1/25
9 II–IV right 1/27
10 II–V right 1/14
11 II–V left 3/14
12 I–V right 1/39
13 I–IV right 1/21
14 I 1/1
15 I–II left 2/4
16 I–IV left 0/29 (after lymph 
node excision)
17 I–IV right 0/12 (after lymph 
node excision)
18 II–IV left 1/9
19 I–IV both sides 8/51 right, 4/37 
left
20 II–V left 1/13
END 
1
II–III right 0/17
END 
2
performed exter-
nally (no informa-
tion)
 
END 
3
II–IV right and 
II–III left
0/15 right, 0/6 
left
END 
4
II–V right 0/2
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75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, 
and 5-fluorouracil 750 mg/m2 days 1–5) 
were administered.
Surgery
The extent of neck dissection and the 
number of positive lymph nodes in oper-
ated patients is shown in . Tab. 2.
Statistics
Statistical calculation was performed us-
ing the statistic program implemented in 
StatView (Version 4.5; SAS Institute, Cary, 
NC, USA).
Results
Outcome
Mean/med i an  fo l l ow-up   was 
 31.6/30.5 months (range 3–78 months). 
The 3-year overall survival rate was 76%. 
The 3-year mucosal control rate, nod-
al control rate, and distant metastasis-
free survival were 100, 93, and 88%, re-
spectively (. Fig. 4). Two patients with 
a nodal mass of 63 and 116 ccm, respec-
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Abstract
Purpose. The goal of the present study 
was to evaluate the outcome of risk-adapt-
ed planning treatment volumes (PTVs) in pa-
tients with cervical lymph node metasta-
ses of unknown primary cancer (UPC) treat-
ed with intensity-modulated radiotherapy 
(IMRT).
Patients and material. Between January 
2006 and November 2012, 28 patients with 
cervical lymph node metastases of UPC were 
treated in our institution with IMRT either 
postoperatively (n=20) or as definitive treat-
ment (n=8). Nodal involvement distributed 
as follows: N1 (n=2), N2a (8), N2b (10), N2c 
(4), and N3 (4). Systemic therapy with cispl-
atin or cetuximab was added concomitant-
ly in 20 of 28 patients (71%). Radiotherapy 
using simultaneously integrated boost (SIB-
IMRT) was carried out with 2.0 or 2.11 Gy sin-
gle doses up to 66/70 Gy.
Results. Mean/median follow-up was 
31.6/30.5 months (range 3–78 months). In all, 
15 of 28 patients were treated with unilater-
al SIB-IMRT (54%). An elective PTV to the con-
tralateral oropharynx and contralateral lev-
el II–III lymph nodes was carried out in 8 pa-
tients with PET-CT suspected but not histo-
logically proven involvement, recurrences or 
former tumor of the oropharynx. More ex-
tended treatment fields were reserved for pa-
tients with N2c or bilaterally N3 status (n=5). 
The 3-year overall survival, mucosal control, 
neck control and distant metastasis-free sur-
vival rates were 76, 100, 93, and 88%, respec-
tively. No patient suffered from a locoregional 
recurrence. Two patients treated with radio-
therapy alone had persistent nodal disease. 
No grade II or higher late sequel has been ob-
served.
Conclusion. Our single center approach to 
treat patients with cervical lymph node me-
tastases of UPC with individualized, risk-
adapted SIB-IMRT resulted in high locore-
gional tumor control and was well tolerated.
Keywords
Radiotherapy, intensity-modulated · 
Treatment outcome · Neoplasm metastasis, 
unknown primary · Cisplatin · Cetuximab
Individualisierter IMRT-Bestrahlungsansatz bei zervikalen Lymph-
knotenmetastasen mit unbekanntem Primärtumor
Zusammenfassung
Ziel. Evaluation von intensitätsmoduliert-
er Radiotherapie (IMRT) mit risikoadaptierten 
Planungszielvolumina („planning treatment 
volumes“, PTVs) bei Patienten mit zervikalen 
Lymphknotenmetastasen bei unbekanntem 
Primarius („unknown primary cancer“, UPC).
Patienten und Methoden. Zwischen Janu-
ar 2006 und November 2012 wurden 28 Pa-
tienten mit zervikalen Lymphknotenmetas-
tasen eines UPC in unserer Abteilung mit 
IMRT entweder postoperativ (n=20) oder 
definitiv (n=8) behandelt. Das Ausmaß des 
Lymphknotenbefalls stellte sich folgender-
maßen dar: N1 (n=2), N2a (n=8), N2b (n=10), 
N2c (n=4) und N3 (n=4). Bei 20/28 Patient-
en (71%) wurde eine simultane Systemthe-
rapie mit Cisplatin oder Cetuximab appliziert. 
Die Bestrahlung mit integriertem Boost (SIB-
IMRT) erfolgte in Einzeldosen von 2,0 oder 
2,11 Gy bis zu einer Gesamtdosis von 66 bis 
70 Gy.
Ergebnisse. Die durchschnittliche/me-
diane Nachbeobachtungszeit betrug 
31,6/30,5 Monate (Spanne 3–78 Monate). 
Von 28 Patienten wurden 15 mit einer uni-
lateralen SIB-IMRT behandelt (54%). Bei 8 Pa-
tienten mit histologisch nicht bestätigten, 
suspekten Befunden im PET-CT, Rezidiven 
oder Zustand nach Oropharynxtumoren 
wurde eine elektive Bestrahlung des kontra-
lateralen Oropharynx und der kontralateralen 
Level-II- bis Level-III-Lymphknoten durchge-
führt. Darüberhinausgehende Erweiterungen 
des PTV wurden bei Patienten mit N2c- 
oder bilateralem N3-Status durchgeführt 
(n=5). Das Gesamtüberleben, die Mukosa-
kontrolle, die lokale Tumorkontrolle und das 
fernmetastasenfreie Überleben nach 3 Jahren 
betrugen 76, 100, 93 und 88%. Kein Patient 
erlitt ein lokoregionäres Rezidiv. Bei 2 Patient-
en persistierte der Lymphknotenbefund nach 
definitiver Radiotherapie. Grad II oder höher-
gradige Spätnebenwirkungen wurden nicht 
beobachtet.
Schlussfolgerung. Die Behandlung von Pa-
tienten mit zervikalen Lymphknotenmetas-
tasen eines UPC mit einer individualisierten, 
risikoadaptierten SIB-IMRT führt zu einer ho-
hen lokoregionären Tumorkontrolle und ist 
gut tolerabel.
Schlüsselwörter
Intensitätsmodulierte Strahlentherapie · 
Behandlungsergebnis · 
Neoplasiemetastasierung, unbekannter 
Primarius · Cisplatin · Cetuximab
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tively, suffered from nodal persistence 
following definitive radio- and radio-
chemotherapy. No patient developed a 
nodal recurrence. By the time of analy-
sis 9 patients were dead: 6/9 for other rea-
sons than UPC [sepsis, severe pneumo-
nia (not aspiration induced) and cranial 
bleeding], 3 patients suffered from a pro-
gressive second malignancy (1 sigma-car-
cinoma, 2 lung cancers). Five of 28 pa-
tients (18%) developed distant metasta-
ses [brain (n=2), bones (n=4), liver (n=2), 
lung (n=1)], 4, 5, 6, 19, and 36 months after 
completion of RT. The patients with nod-
al persistence were inoperable and due to 
their poor general condition, comorbidity 
(gastrointestinal malignancy) and/or age, 
no systemic therapy was carried out. Lo-
cally no complications were observed dur-
ing follow-up.
Planning treatment volumes
Unilateral SIB-IMRT was performed in 
15/28 patients (54%), either postopera-
tively (n=11) or as definitive treatment 
(n=4). In 2 of 15 patients unilateral lymph 
nodes with contralateral mucosa was ir-
radiated (10 to <20 Gy to the contralateral 
pathways, . Fig. 3). In case of risk factors 
(see methods) we enlarged treatment vol-
umes to the contralateral lymph node sites 
[n=13 (46%), postoperatively: 9, defini-
tive: 4]. Contralateral elective PTVs usu-
ally included level II and III and the con-
tralateral oropharyngeal mucosa (54 Gy). 
Dose prescriptions for different treatment 
volumes are summarized in . Tab. 3. An 
overview of the lymphatic pathways and 
the mucosal areas included in the PTVs is 
shown in . Tab. 4.
Systemic therapy
A total of 20 patients received systemic 
therapy. In 14 of 17 patients receiving che-
motherapy, cisplatin had to be stopped af-
ter 1 (n=3), 2 (n=2), 3 (n=4), and 4 (n=5) 
cycles due to rising levels of creatinine 
(n=6), cytopenia (n=3), reduced gener-
al condition (n=4), or tinnitus (n=2). In 
6 of the latter a switch to cetuximab was 
performed. Three patients received ce-
tuximab as first choice due to previously 
diagnosed chronic renal failure or hear-
ing impairment. Side effects of cetux-
imab therapy were acneiform skin reac-
tion (grade III, n=3). One patient devel-
oped a grade IV allergic reaction.
Treatment tolerance
Early side effects
Grade III acute radiation induced der-
matitis was observed in 11 patients (39%). 
Three patients suffered from cetuximab-
related acneiform skin reaction grade III 
(11%). One patient reacted with a grade IV 
anaphylactic shock on loading dose cetux-
imab and had to be treated on intensive 
care unit before he fully recovered. One 
patient developed a grade III glottis ede-
ma in the last week of definitive radiother-
apy which resolved a few weeks after treat-
ment completion without any invasive 
therapy (glucosteroids only). This patient 
had a N3 disease and was only treated uni-
laterally due to reduced general condition. 
He died from cranial bleeding 3 months 
after completion of radiotherapy.
During radiochemotherapy, 3 patients 
had to be hospitalized due to reduced 
general condition. One patient having re-
ceived bilateral IMRT received a gastric 
tube to ensure nutrition. All acute adverse 
effects were reversible.
Late term effects
No grade II or higher late sequel was 
seen.
Tab. 3 Simplified description of doses and planning treatment volumes applied, based on 
lymph node involvement in patients with cervical lymph node metastases of unknown pri-
mary cancer treated in our institution with SIB-IMRT
Affected lymph node levelsa 70/66 Gy 60 Gy 54 Gy
Level I (n=2) Bilateral level I Bilateral I, III
Bilateral OP
Ipsilateral SCR
Ipsilateral level IV, V
Ipsilateral RPN
Level II (n=18) Ipsilateral level 
II–III
Ipsilateral OP Ipsilateral SCR
Ipsilateral level IV, V
Ipsilateral level IB
Ipsilateral RPN
Level III (n=9) Ipsilateral level 
II–III
Ipsilateral IV Ipsilateral SCR
Ipsilateral level IV, V
Ipsilateral RPN
Ipsilateral HP
Level IVb (n=5) Ipsilateral level 
(II),I, IV
 Ipsilateral SCR
Ipsilateral level V
Ipsilateral RPN
Ipsilateral HP
Higher risk for bilateral involve-
ment (additionally to the vol-
umes described above) (n=9)
  Contralateral level II–III
Contralateral OP
OP oropharynx, HP hypopharynx, RPN retropharyngeal nodes, SCR supraclavicular lymph node region. aIn case 
of N2c and bilateral N3 status bilaterally radiation was performed. bLevel IV and V were not involved solitary.
Tab. 4 Elective mucosal irradiation. Simplified description (individual adaption due to in-
volved lymph node levels). Examples shown in . Fig. 1 and . Fig. 2
RT volumes
Lymphatic regions included Mucosa included
Oropharyngeal Hypopharyngeal
Postoperative bilateral (n=9) Ipsilateral 54/60 Gy
Contralateral 54 Gy
Ipsilateral 54/60 Gy
Contralateral 54 Gy or not 
included
Postoperative unilateral (n=11) Ipsilateral 54/60 Gy Ipsilateral 54 Gy or not includ-
ed (majority)
Definitive bilateral (n=4) Bilateral 60 Gy (around midline 
54 Gy)
Ipsilateral 54 Gy or only upper 
1/3 54 Gy or not included
Definitive unilateral (n=4) Ipsilateral 54 Gy Ipsilateral 54 Gy or not includ-
ed (majority)
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Discussion
The goal was to evaluate the effectiveness 
of individualized IMRT target volumes 
in patients with cervical lymph nodes of 
UPC.
Planning treatment volumes
Several study groups compared extended 
treatment fields as described above with 
volumes confined to the unilateral lymph 
node side. As some mostly older studies 
show extensive radiation of bilateral neck 
and entire mucosal axis to be superior in 
locoregional control [5, 6, 7], other stud-
ies did not reveal any differences between 
bilateral and unilateral neck irradiation 
[8, 9, 10]. In a different approach Barker 
et al. [11] showed larynx-sparing radio-
therapy to result in a high likelihood of 
locoregional control and survival. Wal-
lace et al. [1] also practicing elimination 
of larynx and hypopharynx from RT por-
tals showed comparable outcomes in a 
larger patient collective (n=179). Patel et 
al. [23] reserved extended RT for patients 
at higher risk of locoregional failure such 
as N2–3 status. Studies dealing with dif-
ferent PTVs in UPC patients are summa-
rized in . Tab. 5. Except for sporadic pa-
tients being treated with IMRT in those 
series most of the patients received RT in 
the pre-IMRT area.
Intensity-modulated radiotherapy
IMRT offers the ability to discriminate be-
tween different target volumes, to deliver 
multiple doses to different targets simulta-
neously and to reduce the rate and severity 
of toxicity [15, 19]. Taking those potential 
Fig. 1 9 Example of a post-
operative bilateral SIB-
IMRT. Planning treatment 
volumes (PTV) with affect-
ed lymph nodes in left lev-
el II, contralateral level II–
III were treated electively 
up to 54 Gy, red line: PTV1 
(TD 66 Gy/2 Gy), blue line: 
PTV2 (TD 60 Gy/1.8 Gy), 
green line: PTV 3 (TD 
54 Gy/1.64 Gy)
Fig. 2 9 Example of a de-
finitive unilateral SIB-IMRT. 
Planning treatment vol-
umes (PTV) with affect-
ed lymph nodes in left lev-
el III.red line: PTV1 (TD 
69.63 Gy/2.11 Gy), blue line: 
PTV2 (TD 59.4 Gy/1.8 Gy), 
green line: PTV 3 (TD 
54.12 Gy/1.64 Gy)
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advantages of IMRT into account several 
recent studies have been published show-
ing the feasibility of this technique in pa-
tients with UPC. The study with the larg-
est patient group (n=52) presented a lo-
cal control rate and a locoregional control 
rate after 5 years of 94 and 88%, respec-
tively ([15], Tab. 6). Nevertheless, in all 
IMRT studies standardized bilateral radi-
ation fields were used for all patients.
Individualized IMRT 
treatment volumes
For every patient in our cohort the RT vol-
ume was defined depending on the poten-
tial risk of lymph node involvement ac-
cording to Eisbruch et al. [24, 25]. This ap-
proach was adapted to patients with UPC. 
A summary of our dose and PTV sched-
ule is shown in . Tab. 3 and . Tab. 4. The 
primary goal was to avoid extensive vol-
umes while treating patients without on-
cological compromise. Boost dose was de-
livered to the involved lymph node areas 
which were usually level II–III/IV. Adja-
cent unilateral lymph node levels were al-
so included and treated up to 54 Gy or 60–
66 Gy, respectively. The rates of mucosal 
and nodal control and overall survival are 
comparable with findings in other stud-
ies (see . Tab. 5 and . Tab. 6). The 2 pa-
tients in our study with persistent disease 
had large tumor masses of 63 and 116 ccm, 
respectively. No patient developed a newly 
diagnosed locoregional failure.
The advantages of IMRT in sparing 
the parotid glands, pharyngeal tissues, 
oral mucosa and mandible bone are well 
documented. In our study, bilateral SIB-
IMRT was carried out in 13/28 (46%) pa-
tients. In those cases, the mean dose of 
the contralateral parotid was kept under 
20 Gy. Chen et al. [13] observed a median 
dose of 23.3 Gy to the contralateral parot-
id gland (compared to 50.5 Gy in conven-
tional 3D treatment). In case of unilateral 
treatment the contralateral parotid gland 
only received a median dose of 6.9 Gy in 
our study which translated to no grade 
II or higher xerostomia. Another advan-
tage of IMRT in unilateral treatment is the 
ability to reduce dysphagia while sparing 
the pharyngeal constrictors. In our series 
only one patient was in need of a tempo-
rary gastric tube.
Chen et al. [14] showed concurrent 
chemoradiation to be associated with sig-
nificant more toxicity without a clear ad-
vantage to overall survival and locore-
gional control in UPC patients. Lacking 
larger randomized trials in patients with 
UPC, concomitant systemic therapy was 
generously given as it was shown to be su-
perior in head in neck cancer patients in 
general especially in presence of certain 
risk factors like positive resection mar-
gins and extra capsular spread [22, 26, 27, 
28]. This is supported by Shoushtari et al. 
[17] who recommend the addition of che-
Fig. 3 9 Example of a post-
operative unilateral SIB-
IMRT including the contra-
lateral mucosa. Planning 
treatment volumes (PTV) 
with affected lymph nodes 
in left level II. red line: PTV1 
(TD 66 Gy/2 Gy), blue line: 
PTV2 (TD 60 Gy/1.8 Gy), 
green line: PTV 3 (TD 
54 Gy/1.64 Gy)
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Fig. 4 9 Neck con-
trol (NC), distant me-
tastasis-free surviv-
al (DMFS), and over-
all survival (OAS) for 
patients with cervi-
cal lymph nodes of un-
known primary can-
cer (UPC) treated with 
SIB-IMRT
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Tab. 5 Studies using different radiation–volume concepts in patients with unknown primary cancer
Study, year Patients
(n)
Surgery only
(%)
RT
(%)
RT + ND
(%)
CTx
(%)
RT volume 5-year OS
(%)
5-year NC
(%)
5-year DFS
(%)Unilateral Bilateral
Reddy and 
Marks 1997 [5]
52 0 40 60 0 Neck: 31% Neck incl. NP, OP, 
HP: 69%
40 73 ipsilat 51
Grau et al. 
2000 [7]
277 8 77 9 0 Neck only: 
9%
Neck incl. NP OP, 
HP,LA: 91%
36 51 48
Christiansen 
2005 [29]
28 0 39 61 18 Neck: 11% Neck (incl. possible 
primary site): 89%
40 73  
Barker et al. 
2005 [11]
17 0 29 71 6  Neck + NP, OP 82  88
Beldi et al. 
2007 [6]
113 0 48 52 19 Neck: 29% Neck:12%
Neck + NP, OP, HP: 
59%
41  27
Patel et al. 
2007 [23]
70 11 65 14 0 Neck: 82% Neck + NP, OP, HP, 
LA 18%
56 84 ipsilat
93 contralat.
62
Ligey et al. 
2009 [8]
95 0 17 83 45 Neck: 57%
Neck + mu-
cosa: 5%
Neck: 1%
Neck + mucosa: 
37%
24   
Wallace et al. 
2011 [1]
179 0 39 61 7 Neck: 3% Neck plus: OC, OP: 
4%
OP, NP: 15%
OP, HP: 1%
NP, OP, HP: 77%
52 81 73
Fakhrian et al. 
2012 [9]
65 0 6 94 56 Neck: 26% Neck, NP, OP, HP, 
LA: 74%
48  48
Total 844 0 6–77 9–94 0–56  47
range: 
24–82
76
range: 
51–93
57
range: 
27–88
RPN retropharyngeal nodes, NP nasopharynx, OP oropharynx, HP hypopharynx, LA larynx, OC oral cavity, CTx chemotherapy, OS overall survival, NC neck control, DFS 
disease-free survival.
Tab. 6 Selective studies using IMRT in patients with cervical lymph node metastases of unknown primary cancer
Study (ref) 
year
Pat RT (%) RT + ND 
(%)
CTx (%) RT volume OS (%) NC (%) DFS (%)
Unilateral Bilateral
Lu 2008 [16] 18 50 50 33  Bilateral neck + putative mucosal 
site incl. NP, OP, RPN
74.2 (2 years) 88.3 (2 
years)
88.2 (2 years)
Madani et al. 
2008 [19]
23 17 83 13  Bilateral neck + extended putative 
mucosal
74.8 (2 years) 87 (2 
years)
76.3 (2 years)
Frank et al. 
2010 [15]
52 75 25 27  Bilateral neck (contralateral without 
Level I/V) entire pharyngeal axis 
33%: without HP, LA
89 (5 years) 94 (5 
years)
88 (5 years)
Shoushtari et 
al.2011  [17]
27 15 75 30  bilateral neck + RPN, Waldeyer’s 
ring
70.9 (5 years) 88.5 (5 
years)
85.2 (5 years)
Sher 2011 
[30]
24 54 46 92  Bilateral neck + musosa incl. NP, OP, 
HP, LA
92 (2 years) 100 (2 
years)
96 (2 years)
Chen et al. 
2011 [13, 14]
27 30 70 63  Bilateral neck + mucosal axis (incl, 
NP, OP, LA, HP)
86 (2 years) 89 (2 
years)
84 (2 years)
Villeneuve et 
al. 2012 [18]
25 93 7 72  Bilateral neck + ipsilateral putative 
pharyngeal mucosa (NP, OP, HP, LA)
100 (3 years) 100 (3 
years)
100 (3 years)
Own cohort 
2014
28 29 71 71 Risk 
adapted
Unilateral: 54% bilateral: 46% 76 (3 years) 93 (3 
years)
81 (3 years)
Total 224 15–93 7–83 13–92 n=15 
(own)
n=209 (93%) 83 (2–5 
years) range: 
71–100
93 (2–5 
years) 
range: 
87–100
86 (2–5 years) 
range:76–100
RPN retropharyngeal nodes, NP nasopharynx, OP oropharynx, HP ypopharynx, LA  larynx, ND neck dissection, RT radiotherapy, CTx chemotherapy, OS overall survival, NC 
neck control, DFS disease-free survival.
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motherapy in UPC cancer patients with 
extracapsular extension and bulky N2 or 
N3 disease.
To summarize, our results are com-
parable to modern IMRT studies as well 
as studies evaluating reduced treatment 
fields (. Tab. 5, 6). We observed no grade 
II or higher late squeals so far. We tried to 
establish some factors standing for a high-
er risk for potential contralateral disease 
and/or mucosa involvement. Those risk 
factors are of course not evidenced based 
and to some extend subjectively motivat-
ed by the treating radio-oncologist. Nev-
ertheless, in the lack of randomized tri-
als, this approach seems to be effective in 
terms of locoregional control so far and 
should be confirmed in a larger patient 
cohort with longer follow-up.
Conclusion
Risk-adapted individualized reduction 
of PTVs is feasible in IMRT treatment of 
cervical lymph node metastases of UPC 
showing high mucosal and nodal con-
trol rates and a very good treatment tol-
erance.
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